Research by Kaiku Health and Oulu University Hospital will be presented exploring the use of machine learning for prediction of symptom onset and continuation for patients on immune-checkpoint inhibitors. The ESMO Immuno-oncology Congress is a leading immune-oncology event and takes place in Geneva (Dec 11-14, 2019). Kaiku Health is a Debiopharm Innovation Fund portfolio company.
